---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-110945"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T13:24:25.866553+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BrainStorm cuts 30% headcount, CMO departs, plans NurOwn Phase 3b trial

## Summary
- Reduction in force of ~30% with estimated severance costs of $450k-$900k, substantially complete by end of 2023.
- Dr. Kirk Taylor steps down as EVP and Chief Medical Officer effective October 18, 2023, not due to any disagreement.
- Company plans double-blind, placebo-controlled Phase 3b U.S. trial for NurOwn in ALS with open-label extension.
- Total resource consumption to be reduced by ~50% to fund ALS development; exploring capital raising options.
- Positions critical to Phase 3b trial and regulatory submission retained; clean room operations streamlined.

## SEC filing metadata
- accession: 0001104659-23-110945
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/tm2328929d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-110945
- JSON: https://secwatch.observer/filing/0001104659-23-110945.json
- Plain text: https://secwatch.observer/filing/0001104659-23-110945.txt

## Key facts
- Executive change
  Dr. Kirk Taylor departed as EVP and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: stepped down
  - Role: EVP and Chief Medical Officer
  source text: Dr. Kirk Taylor, EVP and Chief Medical Officer, stepped down from his post, effective as of October 18, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm
- Restructurings & Charges
  BRAINSTORM CELL THERAPEUTICS INC. announced a restructuring with charges of approximately $450,000-$900,000 (approximately 30%).
  - Type: restructuring
  - Charge: approximately $450,000-$900,000
  - Headcount: approximately 30%
  source text: In connection with the RIF, the Company currently estimates it will incur a range of costs and expenses of approximately $450,000-$900,000, consisting primarily of cash severance costs and one-time termination benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.